BioStem Technologies (BSEM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.04, -3.32% vs the prior close of $2.11.
- Volume 102.40K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BSEM slides 3.3% to $2.04, a 52-week low, 5 down days in a row. Closed at $2.04, -3.32% vs the prior close of $2.11. Day range $1.88–$2.30, opened at $2.15.
BSEM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BSEM slides 3.3% to $2.04, a 52-week low, 5 down days in a row
- Closed at $2.04, -3.32% vs the prior close of $2.11. Day range $1.88–$2.30, opened at $2.15.
- Volume was 102.40K shares, 0.7x its 50-day average of 148.70K.
- Price is -42.0% vs its 50-day average ($3.52) and -53.2% vs its 200-day average ($4.36).
- 52-week range $1.88–$8.40; today's close sits at 2% of that range, 75.7% below the 52-week high.
- That makes 5 straight losses.
Oct 14, 2026 — BSEM slides 6.2% to $2.11, a 52-week low, 4 down days in a row
- Closed at $2.11, -6.22% vs the prior close of $2.25. Day range $2.10–$2.30, opened at $2.16.
- Volume was 70.00K shares, 0.5x its 50-day average of 148.50K — lighter than usual.
- Price is -40.4% vs its 50-day average ($3.54) and -51.7% vs its 200-day average ($4.36).
- 52-week range $2.10–$8.40; today's close sits at 0% of that range, 74.9% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — BSEM slides 7.8% to $2.25, a 52-week low, 3 down days in a row
- Closed at $2.25, -7.79% vs the prior close of $2.44. Day range $2.13–$2.49, opened at $2.49.
- Volume was 112.30K shares, 0.8x its 50-day average of 147.96K.
- Price is -36.9% vs its 50-day average ($3.56) and -48.6% vs its 200-day average ($4.37).
- 52-week range $2.13–$8.40; today's close sits at 2% of that range, 73.2% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — BSEM dips 1.2% to $2.44
- Closed at $2.44, -1.21% vs the prior close of $2.47. Day range $2.37–$2.49, opened at $2.46.
- Volume was 36.80K shares, 0.2x its 50-day average of 149.03K — lighter than usual.
- Price is -31.9% vs its 50-day average ($3.58) and -44.3% vs its 200-day average ($4.38).
- 52-week range $2.25–$8.40; today's close sits at 3% of that range, 71.0% below the 52-week high.
Oct 9, 2026 — BSEM slides 6.4% to $2.47
- Closed at $2.47, -6.44% vs the prior close of $2.64. Day range $2.46–$2.70, opened at $2.60.
- Volume was 66.10K shares, 0.4x its 50-day average of 148.84K — lighter than usual.
- Price is -31.4% vs its 50-day average ($3.60) and -43.7% vs its 200-day average ($4.39).
- 52-week range $2.25–$8.40; today's close sits at 4% of that range, 70.6% below the 52-week high.
Oct 8, 2026 — BSEM jumps 10.5% to $2.64
- Closed at $2.64, +10.46% vs the prior close of $2.39. Day range $2.36–$2.77, opened at $2.40.
- Volume was 252.90K shares, 1.8x its 50-day average of 144.07K.
- Price is -26.9% vs its 50-day average ($3.61) and -40.0% vs its 200-day average ($4.40).
- 52-week range $2.25–$8.40; today's close sits at 6% of that range, 68.6% below the 52-week high.
Oct 7, 2026 — BSEM slides 3.2% to $2.39, a 52-week low
- Closed at $2.39, -3.24% vs the prior close of $2.47. Day range $2.36–$2.69, opened at $2.50.
- Volume was 87.30K shares, 0.6x its 50-day average of 143.07K.
- Price is -34.1% vs its 50-day average ($3.63) and -45.7% vs its 200-day average ($4.40).
- 52-week range $2.25–$8.40; today's close sits at 2% of that range, 71.5% below the 52-week high.
Oct 6, 2026 — BSEM slides 10.3% to $2.47, a 52-week low
- Closed at $2.47, -10.34% vs the prior close of $2.76. Day range $2.45–$2.79, opened at $2.76.
- Volume was 128.60K shares, 0.9x its 50-day average of 141.29K.
- Price is -32.3% vs its 50-day average ($3.65) and -44.0% vs its 200-day average ($4.41).
- 52-week range $2.25–$8.40; today's close sits at 4% of that range, 70.6% below the 52-week high.
Oct 5, 2026 — BSEM rises 0.9% to $2.76
- Closed at $2.76, +0.92% vs the prior close of $2.73. Day range $2.58–$2.83, opened at $2.74.
- Volume was 120.80K shares, 0.9x its 50-day average of 139.51K.
- Price is -25.0% vs its 50-day average ($3.67) and -37.7% vs its 200-day average ($4.42).
- 52-week range $2.25–$8.40; today's close sits at 8% of that range, 67.2% below the 52-week high.
Oct 2, 2026 — BSEM slides 11.1% to $2.73, a 52-week low, 5 down days in a row
- Closed at $2.73, -11.07% vs the prior close of $3.07. Day range $2.69–$3.07, opened at $3.03.
- Volume was 157.70K shares, 1.2x its 50-day average of 136.98K.
- Price is -26.2% vs its 50-day average ($3.70) and -38.3% vs its 200-day average ($4.43).
- 52-week range $2.25–$8.40; today's close sits at 8% of that range, 67.5% below the 52-week high.
- That makes 5 straight losses.
- SEC filings that day: S-1.
BSEM latest news & SEC filings
Every SEC filing by or about BSEM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith-Van Vurst Andrew converted options/RSUs into 250,000 shares at $2.00 (≈$500.00K) on Oct 7, 2026; now holds 1,789,809
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Matuszewski Jason converted options/RSUs into 250,000 shares at $2.00 (≈$500.00K) on Oct 7, 2026; now holds 1,553,551
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Oct 2, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 29, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 29, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Poe Brandon converted options/RSUs into 1,694 shares on Sep 15, 2026; now holds 58,062
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith-Van Vurst Andrew converted options/RSUs into 7,622 shares on Sep 15, 2026; now holds 1,530,235
- Smith-Van Vurst Andrew converted options/RSUs into 9,574 shares on Sep 17, 2026; now holds 1,539,809
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade BSEM
- Last results release: Aug 12, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 6.37% (largest 19.3%). That is a volatile stock.
- Liquidity: about 176.25K shares (≈$359.54K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.04 vs a range of $1.88–$8.40 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 18, 2026; 8-K Aug 12, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BSEM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.15 | 2.30 | 1.88 | 2.04 | 102.40K |
| Oct 14, 2026 | 2.16 | 2.30 | 2.10 | 2.11 | 70.00K |
| Oct 13, 2026 | 2.49 | 2.49 | 2.13 | 2.25 | 112.30K |
| Oct 12, 2026 | 2.46 | 2.49 | 2.37 | 2.44 | 36.80K |
| Oct 9, 2026 | 2.60 | 2.70 | 2.46 | 2.47 | 66.10K |
| Oct 8, 2026 | 2.40 | 2.77 | 2.36 | 2.64 | 252.90K |
| Oct 7, 2026 | 2.50 | 2.69 | 2.36 | 2.39 | 87.30K |
| Oct 6, 2026 | 2.76 | 2.79 | 2.45 | 2.47 | 128.60K |
| Oct 5, 2026 | 2.74 | 2.83 | 2.58 | 2.76 | 120.80K |
| Oct 2, 2026 | 3.03 | 3.07 | 2.69 | 2.73 | 157.70K |
| Oct 1, 2026 | 3.10 | 3.24 | 3.04 | 3.07 | 90.80K |
| Sep 30, 2026 | 3.80 | 3.84 | 3.00 | 3.09 | 332.10K |
| Sep 29, 2026 | 4.00 | 4.10 | 3.81 | 3.83 | 49.80K |
| Sep 28, 2026 | 4.08 | 4.32 | 3.85 | 4.05 | 181.70K |
| Sep 25, 2026 | 3.85 | 4.28 | 3.81 | 4.14 | 276.90K |
| Sep 24, 2026 | 3.78 | 4.05 | 3.78 | 3.88 | 150.50K |
| Sep 23, 2026 | 3.92 | 4.05 | 3.76 | 3.80 | 84.00K |
| Sep 22, 2026 | 4.36 | 4.61 | 3.95 | 3.98 | 129.60K |
| Sep 21, 2026 | 5.20 | 5.25 | 4.40 | 4.40 | 237.50K |
| Sep 18, 2026 | 4.25 | 5.44 | 4.24 | 4.74 | 857.10K |
About BioStem Technologies
BioStem Technologies (BSEM) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in POMPANO BEACH, FL. State of incorporation: FL. Fiscal year ends December 31. SEC CIK 1658678.
BSEM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mark A Glickman | Director | Aug 28, 2026 |
| Hannaway Rayna Lesser | Director | Aug 28, 2026 |
| Jason Matuszewski | Chief Executive Officer | Sep 17, 2026 |
| Vurst Andrew Smith-Van | Chief Operating Officer | Sep 17, 2026 |
| Steven D Sonenreich | Director | Aug 28, 2026 |
| Jodi Ungrodt | Director | Aug 28, 2026 |
| Kenneth Howard Jr Warrington | Director | Sep 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael A Fortunato | Chief Accounting Officer | Sep 17, 2026 |
| Katherine Gorrell | CLCO | Aug 14, 2026 |
| Barry Hassett | Chief Commercial Officer | Sep 11, 2026 |
| Jason Matuszewski | Chief Executive Officer | Sep 17, 2026 |
| Brandon Poe | Chief Financial Officer | Sep 17, 2026 |
| Vurst Andrew Smith-Van | Chief Operating Officer | Sep 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BSEM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $48.82M, total liabilities $21.20M, cash $6.96M (as of Jun 30, 2026).
BSEM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $3.80 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BSEM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.